SEATTLE
,
Dec. 8, 2020
/PRNewswire/ — CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at
3:00 p.m. EST
. The conference will be held in a virtual meeting format.
Presentation details:
Event: The JMP Securities Hematology Summit
Date:
Tuesday, Dec. 15
Time:
3:00 p.m. EST
The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma’s website at
www.ctibiopharma.com
.
About CTI BioPharma Corp.
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in
Seattle, Washington
.
CTI BioPharma Investor Contacts:
Maeve Conneighton
/
Maghan Meyers
+212-600-1902
[email protected]
View original content to download multimedia:
http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-jmp-securities-hematology-summit-on-tuesday-dec-15-301187816.html
SOURCE CTI BioPharma Corp.
